IMAGE

0420/08-08-03

	OSURE STATEMENT 7(c))	Docket No. 0788.00063						
In Re Application Of: Michael A. Tainsky, et al. AUG 0 8 2003								
Serial No.	Filing Date	Examiner	Group Art Unit					
10/004,587	12-04-01	Unknown	Unknown					
Title: NEOEPITOPE DETECTION OF DISEASE USING PROTEIN ARRAYS								
Address to: Assistant Commissioner for Patents Washington, D.C. 20231								
	37 C	FR 1.97(b)						
1. A The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.								
 The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of: 								
☐ the statem	nent specified in 37 CFR 1.97(e);							
	or							
☐ the fee se	the fee set forth in 37 CFR 1.17(p).							
			,					

	OSURE STATEMENT 7(c))	Docket No. 0788.00063			
In Re Application: Michael A. Tainsky, et al.					
Serial No.	Filing Date	Examiner	Group Art Unit		
10/004,587	Filing Date 7RADE 12-04-01	Unknown	Unknown		
NEOEPITOPE DETECT	ION OF DISEASE USING PROT	ΓEIN ARRAYS			
		ment of Fee			
	(Only complete if Applicant ele	ects to pay the fee set forth in 37 CFR 1	.17(p))		
as described belo Charge th Credit any Charge at Certificate of T	w. A duplicate copy of this sheen the amount of yoverpayment. In additional fee required. In a smission by Facsimile* The smission by Facsimile and authorization to charge depositional transmitted to the United States	Certificate of Mailing by	y First Class Mail I fee is being deposited the U.S. Postal Service 7 C.F.R. 1.8 and is nmissioner for Patents,		
Typed or Printed No	ame of Person Signing Certificate	Typed or Printed Name of Pers	on Mailing Certificate		
Mull	PLLC vay, Suite 410	Dated: August 6, 2003			

		-	· · · · · · · · · · · · · · · · · · ·								
		1	Gotlieb, W.H. et al., "Presence of Interleukins in the Ascites of Patients with Ovarian and other Intra-Abdominal Cancers," Cytokine, 4:385-390 (1992).								
PE	2	-1	Consider D.T. et al. "Consequence Statistics, 2000" CA Consequence I Clim 50:7-23 (2000)								
	<u> </u>	<u> </u>	Greenlee, R.T. et al., "Cancer Statistics, 2000" CA Cancer J Clin, 50:7-33 (2000).								
<u> </u>	· (o)	<u>٧</u>	Heath, S. et al., "Induction of Oblique Decision Trees," Machine Learning, 1002-1007 (1993).								
U 8 200	Fice el	٧	Hogdall, E.V. et al., "Predictive Values of Serum Tumour Markers Tetranectin, OVX1, CASA and CA125 in Patients with a Pelvic Mass," <i>Int J Cancer</i> , 89:519-523 (2000).								
& TRADEN	APPE	1	Holschneider, C.H. et al., "Ovarian Cancer: Epidemiology, Biology, and Prognostic Factors," Semin Surg Oncol, 1:3-10 (2000).								
PIRATE		1	Houts, T.M., "Improved 2-Color Normalization For Microarray Analyses Employing Cyanine Dyes," CAMDA (2000); "Critical Assessment of Techniques for Microarray Data Mining," Duke University								
			Medical Center (2000).								
		٧	Jacobs I, et al., "The CA 125 Tumor-Associated Antigen: A Review of the Literature," Hum Reprod 12 (1989).								
		1	Jacobs, I. et al., "Multimodal Approach to Screening For Ovarian Cancer," Lancet, I 268-271 (1988).								
		1	Jacobs, I.J. et al., "Potential Screening Tests for Ovarian Cancer," London, Chapman and Hall Medical, 197-205 (1997).								
		1	Kacinski BM et al., "Macrophage Colony-Stimulating Factor is Produced by Human Ovarian and Endometrial Adenocarcinoma-Derived Cell Lines and is Present at Abnormally High Levels in the Plasma of Ovarian Carcinoma Patients with Active Disease," Cancer Cells, 7:333-337 (1989).								
		1	Kerr, Martin, Churchill, "Analysis of Variance for Gene Expression Microarray Data," Journal of								
		1	Computational Biology (2000). Kim, Si Young et al., "Coordinate Control of Growth and Cytokeratin 13 Expression by Retinoic Acid," Molecular Carcinogenesis, 16:6-11 (1996).								
		7	Kohonen T., "Learning Vector Quantization," In the handbook of brain theory and neural networks, 537-540 (1995).								
			Kohonen T., "Learning Vector Quantization," Neural Networks, 1 (suppl.1):303 (1988).								
	•	1	Lindstrom MS. et al., "p14ARF Homozygous Deletion or MDM2 Overexpression in Burkitt Lymphoma Lines Carrying Wild Type p53," Oncogene. 20(17):2171-7 (2001).								
		٧	MacBeath G. et al., "Printing Proteins as Microarrays for High-Throughput Function Determination," Science, 289:1760-3 (2000).								
		1	Murthy K., "On Growing Better Decision Trees From Data," Unpublished Doctoral Dissertation. John Hopkins University (1995).								
		1	Musavi M. et al., "On the Training of Radial Basis Function Classifiers," Neural Networks 5:595-603 (1992).								
		7	Nakashima M. et al. "Inhibition of Cell Growth and Induction of Apoptotic Cell Death By the Human Tumor-Associated Antigen RCAS1," Nat Med, 5:938-42 (1999).								
		√.	Patsner B. et al., "Comparison of Serum CA 125 and Lipid Associated Sialic Acid (LASA-P) in Monitoring Patients with Invasive Ovarian Adenocarcinoma," Gynecol Oncol, 30(1): 98-103 (1988).								
-		√.	Peng YS. et al., "ARHI is the Center of Allelic Deletion on Chromosome lp31 in Ovarian and Breast Cancers," <i>Int J Cancer</i> , 86:690-4 (2000).								
			Poggio T. et al., "Networks for Approximation and Learning," <i>Proceedings of IEEE</i> 78(9):1481-149 (1990).								
	٠	1	Precup D. et al., "Classification Using Φ-Machines and Constructive Function Approximation," In Proc. 15th International Conf. On Machine Learning, 439-444 (1998).								
		7	Quinlan JR., "C4.5: Programs for Machine Learning," Morgan-Kaufmann (1993).								
		 √ Rumelhart, DE. et al., "Learning Internal Representations by Error Backpropagation," Parallel Distributed Processing: Explorations in the Microstructures of Cognition, MIT Press/Bradford Bo (1986). 									
	-	1	Schmittgen TD. et al., "Quantitative Reverse Transcription-Polymerase Chain Reaction to Study mRNA Decay: Comparison of Endpoint and Real-Time Methods," Anal Biochem, 285:194-204 (2000).								
		1	Schwartz PE. et al., "Circulating Tumor Markers in the Monitoring of Gynecologic Malignancies," Cancer 60:353-361 (1987).								
		1	Sonoda K. et al., "A Novel Tumor-Associated Antigen Expressed in Human Uterine and Ovarian Carcinomas," Cancer, 77:1501-9 (1996).								
22											
EXAM	INER		DATE CONSIDERED								

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

609

PTO/SB/08 (2-92) Sheet <u>1</u> of <u>2</u>

MANUAL OF PATENT EXAMINING PROCEDURE

Form PTO 3449				Docket Number (Optional)		Application Number					
TRADE!						0788.00063		10/004,587			
INFORMATION DISCLOSURE CITATION IN AN APPLICATION						Applicant Michael A. Tainsky, et al.					
IN AN APPLICATION						Filing Date		Group Art Uni	it		
(Hea squaral shoots if nanossam)					12-04-01	•					
(Use several sheets if necessary)						T DOCUMENTS	3				
EXAMINER		- 			١١٠				FILING	DATE	
INITIAL	DO	CUMENT NUMBER	Ĺ	DATE		NAME	CLASS	SUBCLASS	SUBCLASS IF APPROPR		
į											
			FO	DEIGN D	<u></u>	ENT DOCUME	VTS				
	FOREIGN PA				<u> </u>	ENT DOCUME	TRANSLATION				
	DOCKET NUMBER			DATE		COUNTRY	CLASS	SUBCLASS	YES	NO	
				 					1111	110	
	ļ				.						
		OTHER DOCU	IME	NTS (Inc	lud	ing Author, Title, Da	ite Pertin	ent Pages, Etc	c.)		
	11	Alizadeh, AA. et al	., "Di	istinct Types	of	Diffuse Large B-cell	l Lympho	ma Identified	by Gene Ex	pression	
		Profiling," Nature,	403:5	503-511 (20	00)			· · · · · · · · · · · · · · · · · · ·			
	1				r M	Iore Accurate Classif	fications,	Lecture Note	es in Artificia	ાા	
	4,4	Intelligence, 1418:4	426-4	41 (1998).		nd Thurs an Comme	r Co	nvolved in T	vithelial O	rian	
	1	Aunoble, B. et al.,	Maj:	or Uncogene	s a	nd Tumor Suppresso	u Genes 1	шуотуса іл Еў	nuichat Ova:	11411	
	17	Cancer," Int J Once	'Sem	m sErhR1 ^	10).	Epidermal Growth F	actor Lev	els As Tumor	Biomarkers	in	
	'	Women with Stage	III o	r IV Epithel	al (Ovarian Cancer," Ca	ncer Epic	lemiology, Bio	omarkers &		
]	Prevention 8:129-1	37 (1	999).							
	1	Bast, R.C. et al., "A	Rad	lioimmunoa	say	y Using a Monoclona ded, 309: 883-887 (19	l Antiboo	ly to Monitor	the Course o	of	
	17	Bast R C et al "D	eant:	vity of a Ma) <u>171</u>	clonal Antibody with	Human	Ovarian Carci	noma." J. Cl	in Invest.	
	1	68:1331-1337 (198	31).								
	1	Bauer, R. et al., "C	lonin			rization of the Droso	phila Hor	nologue of the	e AP-2 Trans	scription	
		Factor." Oncogene	17:1	911-1922 (1	998	8).					
	7	Berek, J.S. et al., "	Serur	n Interleukii	1-6	Levels Correlate with	h Disease	Status in Pati	ents with Ep	ntnelial	
	+,-	Ovarian Cancer," A	$\frac{mJ}{M}$	Ubstet Gyne	<u>col</u>	164: 1038-1043 (19	71).	Melanomo hu	Gene Ever	ssion	
	1	Brofiling " Nature	1V10le 1060	cuiar Classi 536-540 (20	UU) ITC8	ation of Cutaneous M	angnant l	wicialionia by	ome expre	301VII	
	1	Profiling," Nature, 406:536-540 (2000). ✓ Blake, C. et al., "UCI Machine Learning Respitory Content," (1998).									
	1	V Blake, C. et al., "Oct Machine Learning Respitory Content, (1998). V Boyd, J. et al., "Hereditary Ovarian Cancer: Molecular Genetics and Clinical Implications," Gynecol									
		Oncol 64:196-206	(199')	7).					·		
	1	Breiman, L. et al.,	"Clas	sification ar	d F	Regression Trees," W	adsworth	and Brooks ((1984).		
		The second secon								criptional	
		activation by AP-2	," Mc	ol. Cell Biol,	13	:4174-4185 (1993).					
	7										
<u> </u>	+-	Molecular Carcino	gene	sis, 5:219-2	31	(1992).	0070	3.261 202 (1)	989)		
<u> </u>	14.	Colomon M.D	ie Cl	Trando in C	Al	gorithm," Machine I er Incidence and Mor	rtality" I	ARC Scientific	. Publication	<u></u>	
1	√	Coleman, M.P., et 121:477-498 (1993		richus in C	111C	or including and Mio.	camey, L	. II. OUKINGU	womanioi	,	
	1	Devo. J. et al. "drr), A 1	Novel Protei	n F	expressed at High Cel	ll Density	But Not Duri	ing Growth A	Arrest,"	
	_ [`	DNA and Cell Biol	l 17:4	37-447 (199	98).						
	1	Draghici, S., "The	Cons	traint Baseo	De	ecomposition," accep	ted for pu	iblication in A	Veural Netwo	orks, to	
		appear (2001).									
	√ Einhorn, N. et al., "Prospective Evaluation of Serum CA 125 Levels for Early Detection of Ovarian							arian			
	1.1	Cancer," Obstet G	yneco	01, 80:14-18	<u>(19</u>	192).	oo D:	tors and Ol-	Dradiotic- 1	w Gene	
[1	Golub, T.R. et al., Expression Monito				cation of Cancer: Cla 531-537 (1999).	99 DI2COA	ony and Class	Tremenon (y Gene	
I .	1	I PULLOSSION INTONING	MALLE,	UULUILUE, A	JU.	レンエ レンド (エノノノ)・					